Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer

CONCLUSIONS: Our genomic analysis suggests that high baseline CIN or effective induction of enhanced mutagenesis on targeted therapy underlies rapid progression. Longer response appears to result from a progressive acquisition of genomic or chromosomal instability in the underlying cancer or from the chance event of a new resistance alteration.PMID:38502113 | DOI:10.1158/1078-0432.CCR-23-4005

Source: Clinical Colorectal Cancer - March 19, 2024 Category: Cancer & Oncology Authors: Emily Harrold Fergus Keane Henry Walch Joanne F Chou Jenna Sinopoli Silvia Palladino Duaa H Al-Rawi Kalyani Chadalavada Paolo Manca Sree Chalasani Jessica Yang Andrea Cercek Jinru Shia Marinela Capanu Samuel F Bakhoum Nikolaus Schultz Walid K Chatila Rona Source Type: research